Adv Cancer Res. 2006;95:1-30.

NY-ESO-1: review of an immunogenic tumor antigen.

Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ.

Source

Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

Abstract

In the 9 years since its discovery, cancer-testis antigen NY-ESO-1 has made one of the fastest transitions from molecular, cellular, and immunological description to vaccine and immunotherapy candidate, already tested in various formulations in more than 30 clinical trials worldwide. Its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of cancer patients. An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here.

PMID:: 16860654; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

NY-ESO-1 protein expression and humoral immune responses in prostate cancer. [Prostate. 2004]
NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB. Prostate. 2004 Jun 1; 59(4):440-7.
Review [NY-ESO-1 and cancer immunotherapy]. [Zhongguo Yi Xue Ke Xue Yuan Xu...]
Review [NY-ESO-1 and cancer immunotherapy].
Peng JR, Leng XS. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Aug; 30(4):371-7.
Review NY-ESO-1 immunotherapy for multiple myeloma. [Leuk Lymphoma. 2006]
Review NY-ESO-1 immunotherapy for multiple myeloma.
Szmania S, Tricot G, van Rhee F. Leuk Lymphoma. 2006 Oct; 47(10):2037-48.
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. [Cancer Chemother Pharmacol. 2004]
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, et al. Cancer Chemother Pharmacol. 2004 Jul; 54(1):95-100. Epub 2004 Apr 30.
[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. [Zhonghua Bing Li Xue Za Zhi. 2...]
[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
Zhang WM, Xiao G, Zhang M, Guo AL, Dong Y, Wen JM. Zhonghua Bing Li Xue Za Zhi. 2005 Apr; 34(4):202-5.

See reviews... See all...

Cited by 27 PubMed Central articles

Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. [Spermatogenesis. 2011]
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.
Cheng YH, Wong EW, Cheng CY. Spermatogenesis. 2011 Jul; 1(3):209-220. Epub 2011 Jul 1.
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. [Proc Natl Acad Sci U S A. 2011]
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, et al. Proc Natl Acad Sci U S A. 2011 Oct 4; 108(40):16723-8. Epub 2011 Sep 20.
Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. [World J Hepatol. 2010]
Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma.
Behboudi S, Pereira SP. World J Hepatol. 2010 Jul 27; 2(7):256-60.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

NY-ESO-1: review of an immunogenic tumor antigen.
NY-ESO-1: review of an immunogenic tumor antigen.
Adv Cancer Res. 2006 ;95:1-30.

PubMed
Effect of six-food elimination diet on clinical and histologic outcomes in eosin...
Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis.
Clin Gastroenterol Hepatol. 2006 Sep ;4(9):1097-102. Epub 2006 Jul 21 .

PubMed
An informed decision? Breast cancer patients and their knowledge about treatment...
An informed decision? Breast cancer patients and their knowledge about treatment.
Patient Educ Couns. 2006 Dec ;64(1-3):303-12. Epub 2006 Jul 24 .

PubMed
Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimul...
Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats.
Eur J Pharmacol. 2006 Aug 21 ;544(1-3):181-7. Epub 2006 Jun 29 .

PubMed
Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELI...
Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART).
Clin Chim Acta. 2007 Jan ;375(1-2):162-4. Epub 2006 Jun 20 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

NY-ESO-1: review of an immunogenic tumor antigen.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 27 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information